Artera Secures FDA Clearance for AI Breast Cancer Test
Artera has received U.S. Food and Drug Administration clearance for its ArteraAI Breast test, marking a significant milestone in the use of artificial intelligence for cancer diagnostics and personalized treatment planning.
The company announced that ArteraAI Breast is now the first and only FDA-cleared digital pathology-based risk stratification tool designed for patients with early-stage hormone receptor-positive (HR+), HER2-negative invasive breast cancer. The clearance further expands Artera’s growing AI oncology platform, which already includes FDA-cleared products in prostate cancer.
The approval comes alongside recent CE Mark certifications in Europe for both the ArteraAI Prostate Biopsy Assay and the ArteraAI Breast Cancer Assay, signaling the company’s broader push into global oncology diagnostics markets.
ArteraAI Breast uses multimodal artificial intelligence technology to analyze digitized pathology images together with patient clinical data. The software generates an AI-derived risk score intended to help clinicians assess the likelihood of distant metastasis in patients diagnosed with early-stage HR+/HER2- breast cancer.
The tool categorizes patients into low-risk and high-risk groups based on predefined thresholds, helping physicians better understand disease progression risks and potentially tailor treatment intensity more precisely.
Breast cancer treatment decisions, particularly in early-stage HR+/HER2- disease, often involve complex evaluations of tumor biology, patient characteristics, and recurrence risk. Determining whether patients may benefit from chemotherapy or less intensive treatment approaches can be challenging, especially when balancing effectiveness against side effects and quality of life considerations.
Artera said its platform is designed to provide clinicians with faster and more consistent pathology-based risk assessments directly within existing diagnostic workflows. Unlike some genomic testing approaches, the system uses routine surgical resection samples and does not require additional tissue collection or separate laboratory processing.
The company noted that same-day results can be delivered alongside standard pathology reports, potentially reducing delays in treatment planning.
Andre Esteva, Chief Executive Officer and co-founder of Artera, described the FDA clearance as an important step in expanding the company’s AI-driven oncology platform across multiple cancer types.
“Breast cancer care is highly nuanced, with treatment decisions that depend on individualized risk,” Esteva said. “Our goal remains consistent across prostate and breast cancer, and beyond: to help clinicians translate complex data into more precise, personalized treatment decisions across the cancer journey.”
Clinical findings presented at the 2025 San Antonio Breast Cancer Symposium evaluated the model’s performance in early-stage breast cancer and suggested the technology may help identify patients more likely to benefit from chemotherapy in certain settings.
Dr. Eric Winer, director of the Yale Cancer Center and a medical oncologist, said the technology could improve both workflow efficiency and collaboration between pathology and oncology teams.
“Using AI and digital pathology has the potential to streamline operational workflows, while creating a strong interdisciplinary linkage between oncology and pathology,” Winer said. “This approach may further improve clinicians’ ability to help patients make the best treatment decisions.”
The clearance reflects growing momentum for AI-driven tools in oncology, as healthcare providers increasingly adopt digital pathology and machine learning technologies to improve diagnostic precision, accelerate workflows, and support personalized cancer care strategies.